Annaliesa S. Anderson

Pfizer (United States)

Papers

1

Total Citations

12

H-Index

1

About

Dr. Annaliesa S. Anderson is a distinguished microbiologist and infectious disease researcher whose work has significantly advanced our understanding of Clostridioides difficile infections. Her primary research focuses on developing innovative diagnostic tools and therapeutic strategies for C. difficile, a major cause of healthcare-associated diarrhea. Dr. Anderson's most notable contribution is the development and clinical validation of an automated cell cytotoxicity neutralization assay, a groundbreaking method for detecting C. difficile toxins in stool samples. This assay, detailed in her 2021 paper with 12 citations, offers a more efficient and reliable alternative to traditional diagnostic approaches, improving patient outcomes by enabling faster, more accurate detection. Her work bridges the gap between laboratory research and clinical application, demonstrating a commitment to translational science. Dr. Anderson's achievements highlight her expertise in assay development and her role in combating antimicrobial-resistant pathogens, making her a key figure in infectious disease research and a valuable resource for students and researchers seeking to understand the complexities of C. difficile diagnostics.

Research Focus

Key Achievements

1
H-Index
1
Papers
12
Total Citations
12
Avg Citations/Paper
🏆 Most Cited Paper
Development and clinical validation of an automated cell cytotoxicity neutralization assay for detecting Clostridioides difficile toxins in clinically relevant stools samples
12 citations · 2021
📈 Most Prolific Year: 2021 (1 Papers)
🤝 Key Collaborators: 11
🏛 Institutions: Pfizer (United States)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago